CV Sciences Q3 revenue falls 7% amid regulatory pressure
CVSI•CV Sciences reported third-quarter revenue of $3.03 million, down 7% year over year, and a net loss of $93,000. Adjusted EBITDA and operating income turned positive, with operating income at $377,000.
1. Quarterly results
CV Sciences said lower sales volumes and average prices, which it attributed to restrictive federal and state regulations, drove the revenue decline. Forty-eight percent of net revenue came from products launched since January 2023. The company said it is monitoring potential restrictive federal regulations set for December 11, 2026, and plans to focus on brand strength and expansion into broader wellness categories.
